Table 1 SUCCESS patient characteristics before and after chemotherapy for EFC#93 serum DNAme
From: Methylation patterns in serum DNA for early identification of disseminated breast cancer
Characteristic | Before chemotherapy | After chemotherapy | |||||
|---|---|---|---|---|---|---|---|
EFC#93– (%) | EFC#93+ (%) | P valuea | EFC#93– (%) | EFC#93+ (%) | P valuea | ||
Patients (n) | 385 (91.9) | 34 (8.1) | 371 (89.4) | 44 (10.6) | |||
Age (mean ± SD) | 53.7 ± 10.3 | 55.2 ± 10.1 | 0.380 | 53.5 ± 10.4 | 56.2 ± 9.3 | 0.097 | |
Menopausal status | Premenopausal | 165 (42.9) | 15 (44.1) | 1.000 | 165 (44.5) | 15 (34.1) | 0.202 |
Postmenopausal | 220 (57.1) | 19 (55.9) | 206 (55.5) | 29 (65.9) | |||
Stage (T) | T1 | 158 (41.0) | 9 (26.5) | 0.110 | 157 (42.3) | 10 (22.7) | 0.014 |
T2–4 | 227 (59.0) | 25 (73.5) | 214 (57.7) | 34 (77.3) | |||
Nodes (N) | NO | 130 (33.9) | 7 (20.6) | 0.130 | 124 (33.4) | 13 (30.2) | 0.735 |
N1–3 | 254 (66.1) | 27 (79.4) | 247 (66.6) | 30 (69.8) | |||
Histology | Invasive ductal | 310 (80.5) | 25 (73.5) | 0.370 | 296 (79.8) | 36 (81.8) | 0.844 |
Others | 75 (19.5) | 9 (26.5) | 75 (20.2) | 8 (18.2) | |||
Grading | Grade 1/2 | 199 (51.7) | 16 (47.1) | 0.721 | 190 (51.2) | 23 (52.3) | 1.000 |
Grade 3 | 186 (48.3) | 18 (52.9) | 181 (48.8) | 21 (47.7) | |||
Estrogen (ER) receptor | ER– | 128 (33.2) | 10 (29.4) | 0.708 | 128 (34.5) | 10 (22.7) | 0.130 |
ER+ | 257 (66.8) | 24 (70.6) | 243 (65.5) | 34 (77.3) | |||
Progesterone (PR) receptor | PR– | 155 (40.4) | 11 (32.4) | 0.465 | 150 (40,5) | 16 (36.4) | 0.629 |
PR+ | 229 (59.6) | 23 (67.6) | 220 (59.5) | 28 (63.6) | |||
HER2 status | HER2– | 294 (77.0) | 24 (70.6) | 0.403 | 276 (75.0) | 38 (86.4) | 0.132 |
HER2+ | 88 (23.0) | 10 (29.4) | 92 (25.0) | 6 (13.6) | |||
Surgery | Breast conserving | 273 (70.9) | 16 (47.1) | 0.006 | 264 (71.2) | 23 (52.3) | 0.015 |
Mastectomy | 112 (29.1) | 18 (52.9) | 107 (28.8) | 21 (47.7) | |||
Chemotherapy | FEC-D | 193 (50.1) | 18 (52.9) | 0.858 | 186 (50.1) | 22 (50.0) | 1.000 |
FEC-DG | 192 (49.9) | 16 (47.1) | 185 (49.9) | 22 (50.0) | |||
Bisphosphonates | Zometa 2 years | 193 (50.1) | 17 (50.0) | 1.000 | 185 (49.9) | 23 (52.3) | 0.874 |
Zometa 5 years | 192 (49.9) | 17 (50.0) | 186 (50.1) | 21 (47.7) | |||
Circulating tumor cells (CTCs) | CTC– before chemo | 316 (82.1) | 20 (58.8) | 0.003 | 303 (81.7) | 32 (72.3) | 0.160 |
CTC+ before chemo | 69 (17.9) | 14 (41.2) | 68 (18.3) | 12 (27.7) | |||
CTC– after chemo | 304 (79.0) | 27 (79.4) | 1.000 | 302 (81.4) | 28 (63.6) | 0.009 | |
CTC+ after chemo | 81 (21.0) | 7 (20.6) | 69 (18.6) | 16 (36.4) | |||